Register for our free email digests:
Division of Medtronic PLC
Latest From Cystic Fibrosis Foundation Therapeutics Inc.
Safety was the primary endpoint in a Phase II study for the inflammation-targeting drug anabasum, but Corbus believes an efficacy signal viewed outside of the secondary endpoints justifies further development.
Alcresta Pharmaceuticals Inc. aims to combat malabsorption, with an initial focus on enzyme deficiencies, for people with gastrointestinal disorders and rare diseases. It is developing a pipeline of point-of-care nutritional products tailored to maximize the absorption of calories or specific nutrients, based on cartridges enclosing enzymes immobilized onto polymer beads.
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
Surgical Equipment & Devices
- Minimally or Less Invasive
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Medtronic PLC
- Senior Management
Bill Hoffman, CEO
Linda Spain, CFO
Andrew Keene, Dir., Bus. Dev.
- Contact Info
Phone: (713) 275-2063
8058 El Rio St.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.